ArticleClinical mass spectrometry (Del Mar, Calif.)2016
SPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids.
Article in Clinical mass spectrometry (Del Mar, Calif.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 78 citations in OpenAlex.
- Unveiling the anticancer potential of medicinal plants: metabolomics and analytical tools in phytomedicine.Molecular diversity · 2026Review
- Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives.Proteomics · 2026Review
- Overcoming a false-positive mechanism in RapidFire MRM-based high throughput screening.SLAS discovery : advancing life sciences R & D · 2025Article
- Reference library for suspect screening of environmental toxicants using ion mobility spectrometry-mass spectrometry.Communications chemistry · 2025Article
- The evolution of analytical techniques for multiplex analysis of protein biomarkers.Expert review of proteomics · 2025Review
- Facile Synthesis of 3D NC-rGO@Ni-Foam Nanonetwork as a Binder-Free Hybrid Electrode Material for Ultrahigh Capacitance Applications.ACS omega · 2025Article
- Exploring new frontiers in type 1 diabetes through advanced mass-spectrometry-based molecular measurements.Trends in molecular medicine · 2024Review
- AutonoMS: Automated Ion Mobility Metabolomic Fingerprinting.Journal of the American Society for Mass Spectrometry · 2024Article
- Microfluidics enabled multi-omics triple-shot mass spectrometry for cell-based therapies.Biomicrofluidics · 2024Article
- Development of an Automated, High-Throughput Methodology for Native Mass Spectrometry and Collision-Induced Unfolding.Analytical chemistry · 2023Article
- Metabolomic, photoprotective, and photosynthetic acclimatory responses to post-flowering drought in sorghum.Plant direct · 2023Article
- A High-Throughput Ion Mobility Spectrometry-Mass Spectrometry Screening Method for Opioid Profiling.Journal of the American Society for Mass Spectrometry · 2022Article
- A dynamic rhizosphere interplay between tree roots and soil bacteria under drought stress.eLife · 2022Article
- High-Resolution Demultiplexing (HRdm) Ion Mobility Spectrometry-Mass Spectrometry for Aspartic and Isoaspartic Acid Determination and Screening.Analytical chemistry · 2022Article
- DEIMoS: An Open-Source Tool for Processing High-Dimensional Mass Spectrometry Data.Analytical chemistry · 2022Article
- A Preprocessing Tool for Enhanced Ion Mobility-Mass Spectrometry-Based Omics Workflows.Journal of proteome research · 2022Article
- Combining Isotopologue Workflows and Simultaneous Multidimensional Separations to Detect, Identify, and Validate Metabolites in Untargeted Analyses.Analytical chemistry · 2022Article
- Insights and prospects for ion mobility-mass spectrometry in clinical chemistry.Expert review of proteomics · 2022Article
- Utilizing ion mobility spectrometry-mass spectrometry for the characterization and detection of persistent organic pollutants and their metabolites.Analytical and bioanalytical chemistry · 2022Article
- Improving the Speed and Selectivity of Newborn Screening Using Ion Mobility Spectrometry-Mass Spectrometry.Analytical chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 1 country.
Funding
Abstract
Characterization of endogenous metabolites and xenobiotics is essential to deconvoluting the genetic and environmental causes of disease. However, surveillance of chemical exposure and disease-related changes in large cohorts requires an analytical platform that offers rapid measurement, high sensitivity, efficient separation, broad dynamic range, and application to an expansive chemical space. Here, we present a novel platform for small molecule analyses that addresses these requirements by combining solid-phase extraction with ion mobility spectrometry and mass spectrometry (SPE-IMS-MS). This platform is capable of performing both targeted and global measurements of endogenous metabolites and xenobiotics in human biofluids with high reproducibility (CV 6 3%), sensitivity (LODs in the pM range in biofluids) and throughput (10-s sample-to-sample duty cycle). We report application of this platform to the analysis of human urine from patients with and without type 1 diabetes, where we observed statistically significant variations in the concentration of disaccharides and previously unreported chemical isomers. This SPE-IMS-MS platform overcomes many of the current challenges of large-scale metabolomic and exposomic analyses and offers a viable option for population and patient cohort screening in an effort to gain insights into disease processes and human environmental chemical exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.